Literature DB >> 22140254

Minimal tolerance to a tumor antigen encoded by a cancer-germline gene.

Ivo J Huijbers1, Saïdi M Soudja, Catherine Uyttenhove, Michel Buferne, Else-Marit Inderberg-Suso, Didier Colau, Luc Pilotte, Céline G Powis de Tenbossche, Patrick Chomez, Francis Brasseur, Anne-Marie Schmitt-Verhulst, Benoît J Van den Eynde.   

Abstract

Central tolerance toward tissue-restricted Ags is considered to rely on ectopic expression in the thymus, which was also observed for tumor Ags encoded by cancer-germline genes. It is unknown whether endogenous expression shapes the T cell repertoire against the latter Ags and explains their weak immunogenicity. We addressed this question using mouse cancer-germline gene P1A, which encodes antigenic peptide P1A(35-43) presented by H-2L(d). We made P1A-knockout (P1A-KO) mice and asked whether their anti-P1A(35-43) immune responses were stronger than those of wild-type mice and whether P1A-KO mice responded to other P1A epitopes, against which wild-type mice were tolerized. We observed that both types of mice mounted similar P1A(35-43)-specific CD8 T cell responses, although the frequency of P1A(35-43)-specific CD8 T cells generated in response to P1A-expressing tumors was slightly higher in P1A-KO mice. This higher reactivity allowed naive P1A-KO mice to reject spontaneously P1A-expressing tumors, which progressed in wild-type mice. TCR-Vβ usage of P1A(35-43)-specific CD8 cells was slightly modified in P1A-KO mice. Peptide P1A(35-43) remained the only P1A epitope recognized by CD8 T cells in both types of mice, which also displayed similar thymic selection of a transgenic TCR recognizing P1A(35-43). These results indicate the existence of a minimal tolerance to an Ag encoded by a cancer-germline gene and suggest that its endogenous expression only slightly affects diversification of the T cell repertoire against this Ag.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22140254     DOI: 10.4049/jimmunol.1002612

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

Review 1.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Authors:  Pierre G Coulie; Benoît J Van den Eynde; Pierre van der Bruggen; Thierry Boon
Journal:  Nat Rev Cancer       Date:  2014-02       Impact factor: 60.716

Review 2.  Improving T cell responses to modified peptides in tumor vaccines.

Authors:  Jonathan D Buhrman; Jill E Slansky
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

3.  Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice.

Authors:  Matthias Obenaus; Catarina Leitão; Matthias Leisegang; Xiaojing Chen; Ioannis Gavvovidis; Pierre van der Bruggen; Wolfgang Uckert; Dolores J Schendel; Thomas Blankenstein
Journal:  Nat Biotechnol       Date:  2015-03-16       Impact factor: 54.908

4.  Distinct patterns of cytolytic T-cell activation by different tumour cells revealed by Ca2+ signalling and granule mobilization.

Authors:  Melissa Frick; Pierre Mouchacca; Grégory Verdeil; Yannick Hamon; Cyrille Billaudeau; Michel Buferne; Mathieu Fallet; Nathalie Auphan-Anezin; Anne-Marie Schmitt-Verhulst; Claude Boyer
Journal:  Immunology       Date:  2016-11-02       Impact factor: 7.397

Review 5.  Epigenetic mechanisms of tumor resistance to immunotherapy.

Authors:  Natalia Arenas-Ramirez; Dilara Sahin; Onur Boyman
Journal:  Cell Mol Life Sci       Date:  2018-08-23       Impact factor: 9.261

6.  Aire deficiency promotes TRP-1-specific immune rejection of melanoma.

Authors:  Meng-Lei Zhu; Anil Nagavalli; Maureen A Su
Journal:  Cancer Res       Date:  2013-01-31       Impact factor: 12.701

7.  DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses.

Authors:  Heath A Smith; Brian T Rekoske; Douglas G McNeel
Journal:  Vaccine       Date:  2014-01-31       Impact factor: 3.641

8.  Split T-cell tolerance as a guide for the development of tumor antigen-specific immunotherapy.

Authors:  Takemasa Tsuji; Sacha Gnjatic
Journal:  Oncoimmunology       Date:  2012-05-01       Impact factor: 8.110

Review 9.  Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response.

Authors:  Michel DuPage; Tyler Jacks
Journal:  Curr Opin Immunol       Date:  2013-03-04       Impact factor: 7.486

Review 10.  Harnessing the antigenic fingerprint of each individual cancer for immunotherapy of human cancer: genomics shows a new way and its challenges.

Authors:  Pramod K Srivastava; Fei Duan
Journal:  Cancer Immunol Immunother       Date:  2013-04-19       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.